Home › Compare › ORPHY vs EQR

ORPHY vs EQR: Dividend Comparison 2026

ORPHY yields 6666.67% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ORPHY wins by $1028095347812062.00M in total portfolio value
10 years
ORPHY
ORPHY
● Live price
6666.67%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1028095347812062.00M
Annual income
$998,628,545,336,266,700,000.00
Full ORPHY calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — ORPHY vs EQR

📍 ORPHY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORPHYEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORPHY + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ORPHY pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORPHY
Annual income on $10K today (after 15% tax)
$566,666.67/yr
After 10yr DRIP, annual income (after tax)
$848,834,263,535,826,600,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, ORPHY beats the other by $848,834,263,535,826,600,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORPHY + EQR for your $10,000?

ORPHY: 50%EQR: 50%
100% EQR50/50100% ORPHY
Portfolio after 10yr
$514047673906031.00M
Annual income
$499,314,272,668,133,360,000.00/yr
Blended yield
97.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

ORPHY
No analyst data
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORPHY buys
0
EQR buys
0
No recent congressional trades found for ORPHY or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORPHYEQR
Forward yield6666.67% ✓4.73%
Annual dividend / share$2.00$2.77 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$1028095347812062.00M ✓$40.5K
Annual income after 10y$998,628,545,336,266,700,000.00 ✓$3,819.61
Total dividends collected$1026118102492338.88M ✓$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ORPHY vs EQR ($10,000, DRIP)

YearORPHY PortfolioORPHY Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$677,367$666,666.67$11,248$547.57+$666.1K → ORPHY
2$42,928,313$42,203,530.63$12,701$666.53+$42.92M → ORPHY
3$2,545,616,701$2,499,683,405.64$14,405$814.59+$2545.60M → ORPHY
4$141,255,910,403$138,532,100,533.89$16,413$999.84+$141255.89M → ORPHY
5$7,335,374,338,812$7,184,230,514,680.15$18,795$1,232.92+$7335374.32M → ORPHY
6$356,516,885,536,661$348,668,034,994,132.70$21,639$1,527.95+$356516885.52M → ORPHY
7$16,218,956,689,966,618$15,837,483,622,442,392.00$25,057$1,903.80+$16218956689.94M → ORPHY
8$690,711,023,145,868,900$673,356,739,487,604,600.00$29,197$2,385.87+$690711023145.84M → ORPHY
9$27,539,067,734,387,980,000$26,800,006,939,621,900,000.00$34,250$3,008.70+$27539067734387.95M → ORPHY
10$1,028,095,347,812,062,000,000$998,628,545,336,266,700,000.00$40,467$3,819.61+$1028095347812062.00M → ORPHY

ORPHY vs EQR: Complete Analysis 2026

ORPHY — Stock

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative rare diseases. The company offers heat stock proteins that focuses on the treatment of neurodegenerative diseases by harnessing the cell protective properties of the heat shock response, which protects cells from the accumulation of misfolded proteins, aggregated proteins, and dysfunctional lysosomes. Its lead candidate is the Arimoclomol, which is in clinical development for diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, and Inclusion Body Myositis. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

Full ORPHY Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this ORPHY vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORPHY vs SCHDORPHY vs JEPIORPHY vs OORPHY vs KOORPHY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.